CRL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

987.13M

-1.54%

2.345

-11.83%

999.34M

+1.54%

2.591

+10.74%

1.03B

-0.14%

2.842

-8.9%

Estimates Revision

The market is revising Upward the revenue expectations for Charles River Laboratories International, Inc. (CRL) for FY2025, with the revenue forecasts being adjusted by 0.39% over the past three months. During the same period, the stock price has changed by 28.33%.

Revenue Estimates for FY2025

Revise Upward

+0.39%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.41%

In Past 3 Month

Stock Price

Go Up

+28.33%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast CRL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 192.73 USD with a low forecast of 165.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

165.00

Averages

192.73

High

225.00

Current: 0.000

Low

165.00

Averages

192.73

High

225.00

Mizuho

Neutral

maintain

$174 -> $200

2025-12-18

Reason

Mizuho

Price Target

$174 -> $200

2025-12-18

maintain

Neutral

Reason

Mizuho raised the firm's price target on Charles River to $200 from $174 and keeps a Neutral rating on the shares as part of its 2026 outlook for managed care and health facilities. The firm believes 2026 will be a "pivotal year" for managed care. The sector is at the end of a three-year negative underwriting cycle and margins should improve in commercial, Medicaid and Medicare over the next few years, the analyst tells investors in a research note. As a result, Mizuho is positive on managed care heading into 2026.

JPMorgan

Neutral

maintain

$165 -> $190

2025-12-15

Reason

JPMorgan

Price Target

$165 -> $190

2025-12-15

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Charles River to $190 from $165 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group.

Barclays

NULL -> Overweight

maintain

$210 -> $215

2025-12-15

Reason

Barclays

Price Target

$210 -> $215

2025-12-15

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Charles River to $215 from $210 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

BofA

Michael Ryskin

Neutral -> Buy

upgrade

$185 -> $225

2025-12-15

Reason

BofA

Michael Ryskin

Price Target

$185 -> $225

2025-12-15

upgrade

Neutral -> Buy

Reason

BofA analyst Michael Ryskin upgraded Charles River to Buy from Neutral with a price target of $225, up from $185.

Argus

Hold

Buy

upgrade

$200

2025-11-17

Reason

Argus

Price Target

$200

2025-11-17

upgrade

Hold

Buy

Reason

Argus upgraded Charles River to Buy from Hold with a $200 price target.

Morgan Stanley

Equal Weight

maintain

$170 -> $185

2025-11-11

Reason

Morgan Stanley

Price Target

$170 -> $185

2025-11-11

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Charles River to $185 from $170 and keeps an Equal Weight rating on the shares.

Valuation Metrics

The current forward P/E ratio for Charles River Laboratories International Inc (CRL.N) is 19.20, compared to its 5-year average forward P/E of 22.42. For a more detailed relative valuation and DCF analysis to assess Charles River Laboratories International Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

22.42

Current PE

19.20

Overvalued PE

29.14

Undervalued PE

15.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.98

Current EV/EBITDA

12.73

Overvalued EV/EBITDA

18.99

Undervalued EV/EBITDA

10.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.05

Current PS

2.47

Overvalued PS

4.11

Undervalued PS

2.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areBuying! The buying amount has increased100%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRL News & Events

Events Timeline

No data

News

5.0

01-08NASDAQ.COM

Charles River Labs CEO James Foster to Retire in 2026, Birgit Girshick Appointed Successor

5.0

01-08Newsfilter

Charles River Labs CEO Jim Foster Plans Retirement in May 2026 After 50-Year Career

6.5

2025-12-18Barron's

Bargain Stocks to Consider Beyond the Megacaps: Boeing, Waste Management, and More

People Also Watch

Frequently Asked Questions

What is Charles River Laboratories International Inc (CRL) stock price today?

The current price of CRL is 220.91 USD — it has increased 2.51 % in the last trading day.

What is Charles River Laboratories International Inc (CRL)'s business?

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

What is the price predicton of CRL Stock?

What is Charles River Laboratories International Inc (CRL)'s revenue for the last quarter?

Charles River Laboratories International Inc revenue for the last quarter amounts to 1.00B USD, decreased -0.49 % YoY.

What is Charles River Laboratories International Inc (CRL)'s earnings per share (EPS) for the last quarter?

Charles River Laboratories International Inc. EPS for the last quarter amounts to 1.10 USD, decreased -17.29 % YoY.

What changes have occurred in the market's expectations for Charles River Laboratories International Inc (CRL)'s fundamentals?

How many employees does Charles River Laboratories International Inc (CRL). have?

Charles River Laboratories International Inc (CRL) has 18600 emplpoyees as of January 10 2026.

What is Charles River Laboratories International Inc (CRL) market cap?

Today CRL has the market capitalization of 10.87B USD.